The discovery of unidirectional, ATP-dependent canalicular transport systems (also termed "export pumps") for bile salts, amphiphilic anionic conjugates, lipophilic cations, and phospholipids has opened new opportunities for understanding biliary physiology and the pathophysiology of cholestasis. In addition, ATP-independent canalicular transport systems for glutathione and bicarbonate contribute to (bile acid-independent) bile formation. Canalicular excretion of bile salts and several non-bile acid organic anions is impaired in various experimental models of cholestasis. Recent cloning of several canalicular transport systems now facilitates studies on their molecular regulation in cholestasis. Although the picture is far from complete, experimental evidence now exists that decreased or even absent expression of canalicular transport proteins may explain impaired transport function resulting in hyperbilirubinemia and cholestasis. With the increasing availability of molecular probes for these transport systems in humans, new information on the molecular regulation of canalicular transport proteins in human cholestatic liver diseases is beginning to emerge and should bring new insights into their pathophysiology and treatment. This article gives an overview on molecular alterations of canalicular transport systems in experimental models of cholestasis and discusses the potential implications of these changes for the pathophysiology of cholestasis.
independent mechanisms, followed by modifications along the bile ductules and ducts [1, 2] . Canalicular bile is formed by osmotic filtration of water and small electrolytes via the tight junctions in response to osmotic gradients generated by active transport systems located at the canalicular membrane. The major determinant of canalicular bile formation is the excretion of bile acids into the canaliculus (bile acid-dependent bile flow). In addition, other (non-bile acid) organic anions and cations and their conjugates also osmotically influence bile flow. Canalicular excretion of glutathione and bicarbonate constitute the major components of the bile acid-independent fraction of bile flow, although the contribution of bicarbonate occurs mainly at the level of the bile ductules, particularly when stimulated with hormones and neuropeptides [1, 3] .
Initially it was thought that the major driving force for the canalicular excretion of all biliary constituents was the intracellular negative membrane potential (-35 mV) generated by the Na+ pump (Na+/K+-ATPase) at the basolateral membrane. However, it has become evident that the membrane potential could only account for a 3-fold concentration gradient and thus is insufficient to explain the large gradients (ranging from 100-fold to as high as 1000-fold) observed for bile acids and certain anionic conjugates (e.g., cysteinyl leukotrienes). The discovery of unidirectional, primary active ATP-dependent transport systems at the canalicular membrane has opened new opportunities for understanding biliary physiology and the pathophysiology of cholestasis. These ATP-dependent transport systems belong to the ATP-binding cassette transporter superfamily and share common structural and functional characteristics [4, 5] . At least four ATP-dependent transport systems (also termed "export pumps") have been identified so far at the canalicular membrane ( Figure 1 , left panel): (i) A multidrug export pump (MDRI P-glycoprotein) for hydrophobic cationic compounds (e.g., anticancer drugs, calcium channel blockers, cyclosporin A, various other drugs) [18, 19] , and (ii) a phospholipid pump (MDR3 P-glycoprotein) which probably acts as a phospolipid flippase/translocase [20, 21] [19] . (iii) A conjugate export pump which has recently been cloned in rats [10, 11] and humans [12, 13] and was identified as the canalicular isoform of the multidrug-resistance-associated protein, (MRP) and therefore designated as MRP2. This transport system is functionally also known as the canalicular multispecific organic anion transporter (cMOAT) [14] and mediates the canalicular excretion of a broad range of organic anions, most of which are amphiphilic anionic conjugates with glutathione, glucuronate and sulfate formed by phase II conjugation in the hepatocyte [14] [15] [16] [17] . (iv) A bile salt export pump (canalicular bile acid transporter, cBAT) for monovalent bile salts, which functionally is well characterized [6] [7] [8] [9] but has not been cloned yet.
In addition to these ATP-dependent transport systems, the canalicular membrane also contains several ATP-independent transport systems ( Figure 1 , right panel): Canalicular excretion of reduced glutathione (GSH) is driven by the membrane potential but the molecular identity of this transport system remains currently unclear. Yi et al. [22] reported isolation of a putative rat canalicular GSH transporter (RcGshT), but with the recent availability of the full E. coli genome it became apparent that the sequence of RcGshT is an E. coli gene and represents a cloning artifact [23, 24] . Canalicular bicarbonate secretion is mediated via the Cl-/HCO3-exchanger belonging to a family of anion exchangers (AE) which consists of several members, three of which (AEI, AE2, and AE3) are now well characterized [25] . AE2 is encountered in various tissues, including the liver and secretory epithelia, and plays a major role in mediating hepatic Cl-/HCO3-exchange. The AE2 protein is localized to both canaliculi (mainly in periportal hepatocytes) and the luminal side of both terminal and interlobar bile ducts [26] , consistent with a role for HCO3-excretion (Table 3 ) and outlines potential implications of these changes for the pathophysiology of cholestasis. Furthermore, molecular changes of canalicular transporters in human cholestatic disorders are discussed whenever possible, although this information is still very sparse.
Bile salts
The canalicular excretion of monovalent bile salts is mediated by a canalicular bile acid transporter (cBAT/cbat) whereas the excretion of divalent sulfated and glucuronidated bile salt conjugates is mediated by the conjugate export pump (MRP2/mrp2) (see below). Functional studies in isolated canalicular membrane vesicles have clearly demonstrated inhibition of ATP-dependent transport of monovalent bile salts in various experimental models of cholestasis induced by LPS [29, 30] , EE [28] , cyclosporin A (CSA) [31] .
Since the Vmax of ATP-dependent canalicular bile acid transport is diminished in most of these models of cholestasis [28] [29] [30] , it could be expected that the expression of cbat is down-regulated by these cholestatic agents/injuries. However, the information on the molecular expression of canalicular bile acid transporter(s) in these forms of cholestasis is [33] . This finding could be of interest, since spgp is exclusively expressed in hepatocytes at the canalicular membrane to a similar extent as the mdr2 isoform of P-gp [32, 33] and some authors consider the spgp a candidate for the canalicular bile acid transporter [34] . Alternative candidate genes include the (yet unidentified) mammalian equivalent of a yeast gene (BATip) encoding an ATP-dependent transporter for taurocholate in yeast vacuoles [35] , and a group of 150 to 200-kDa plasma membrane proteins overexpressed in a rat hepatoma-derived HTC cell line resistant to glycocholic acid [36, 37] . The expression of the canalicular enzyme and putative bile acid transporter Ca++-Mg++-ecto-ATPase [38] [39] [40] was decreased after LPS and TNF-a administration in one study [29] , but not in two others [41, 42] . In addition, ecto-ATPase expression also did not change during EE-induced cholestasis [43] and CBDL [44] . However, the true role of ecto-ATPase in canalicular bile acid transport remains controversial, since the sequence of this protein predicts a single membrane-spanning domain and the ATPase activity is oriented toward the extracellular rather than the intracellular domain and can be uncoupled from transport activity [39, 40] , which does not conform to current expectations for an ATP-dependent in-to-out transport protein [16, 45] .
Amphiphilic anionic conjugates
The biliary excretion of various anionic conjugates (e.g., bilirubin diglucuronide, GSH-conjugates, cysteinyl leukotrienes, oxidized glutathione (GSSG), dibromosufophthalein (BSP), divalent bile acid glucuronides and sulfates) is also decreased in several models of intrahepatic (LPS, EE) and extrahepatic cholestasis (CBDL) [28, 30, [46] [47] [48] [49] [50] . Again, these functional studies have revealed decreased Vmax without changes in Km, consistent with a change in the number of functional transporters for these substrates. Recent studies have demonstrated that the expression of the rat canalicular conjugate export pump (mrp2) is profoundly decreased by LPS, EE, and CBDL at the protein level [51] . Mrp2 steady-state mRNA levels are also markedly decreased in LPS and CBDL animals, but remain unchanged in EE-induced cholestasis. The findings in LPS-treated rats and CBDL suggest that the reduction of mrp2 protein levels may result at least in part from a decrease in steady-state mRNA-levels, probably due to a reduction in the rate of gene transcription. Although the half-life of the mrp2 protein is currently unknown, the rapid disappearance of the protein within 16 hr after LPS suggests either that the half-life of this protein is normally short or that it is rapidly degraded during LPS-induced cholestasis. In contrast to LPS and CBDL, mrp2 steady-state mRNA levels did not decline in EE-treated rats, suggesting that the reduction of mrp2 protein levels in this form of cholestasis occurs exclusively by posttranslational mechanisms which remain to be determined.
Decreased mrp2 expression may provide a molecular mechanism explaining impaired excretion of a broad range of endogenous and exogenous organic anions and thereby many biochemical features of cholestasis, including conjugated hyperbilirubinemia and impaired BSP and indocyanine green clearance. The effects on mrp2 expression are most pronounced in LPS-induced cholestasis, consistent with elevations of (mostly conjugated) serum bilirubin as the key-feature of sepsis-associated cholestasis ("jaundice of sepsis") [52, 53] . Preliminary findings from our laboratory suggest, that inflammatory cytokines such as tumor necrosis factor-a and interleukin-1 3 decrease mrp2 mRNA and protein levels in primary rat hepatocytes in vitro, suggesting that the effects of LPS may be mediated through these proinflammatory cytokines. The clinical implications of these findings may not only be restricted to the pathogenesis of cholestasis of sepsis. Several other liver diseases such as total parenteral nutrition-induced cholestasis, alcoholic hepatitis and liver cirrhosis are associated with significant portal vein and systemic endotoxemia and/or elevated levels of inflammatory cytokines [54] [55] [56] [57] . In addition, down-regulation of mrp2 may have broader implications for the pathogenesis of intrahepatic cholestasis, since biliary glutathione (GSH) excretion and thereby bile acid-independent bile flow is diminished in mutant rats with congenitally absent mrp2 protein (see below). Thus, down-regulation of mrp2 expression may represent a primary event in the pathogenesis of intrahepatic cholestasis by reduction of bile acid-independent canalicular bile flow. Finally, decreased mrp2 expression and function during cholestasis may also have important implications for the metabolism and excretion of various potentially toxic endo-and xenobiotics [17, 58] . Drugs such as ampicillin and ceftriaxone are directly excreted into bile by mrp2 [14] [15] [16] , and their biliary excretion may be impaired during cholestasis [59, 60] .
Mutant Groningen Yellow (GY)/transport deficient (TR-) and Eisai hyperbilirubinemic (EHBR) rats have a congenital defect in mrp2 function characterized by absent canalicular transport for various endogenous and exogenous organic anions and are the rat model for the Dubin-Johnson syndrome in humans [14] . Cross-breeding studies among the individual mutant rat strains resulted in jaundiced offspring in either case, indicating that GY/TR-and EHBR rats have an identical (autosomal recessive) defect. Recently, the molecular basis for this hereditary defect in GY/TR-rats has been identified as a singlenucleotide deletion in the mrp2 gene resulting in a frame shift which leads to the introduction of an early stop codon (at amino acid 401) [10] . In EHBR rats, a single nucleotide substitution (but not deletion) also results in the introduction of a premature stop codon (at amino acid 855) [61] . Both mutations lead to absence of the mrp2 protein from the livers of GY/TR-and EHBR rats, respectively [10, 11] . The untranslated mrp2 mRNA is rapidly degraded explaining the very low to absent mRNA levels of mrp2 in these rats. Recently, additional ATP-dependent canalicular conjugate export systems such as MRPlike proteins (MLP 1 and 2) preserved in mutant EHBR rats have been identified [62] and await further molecular characterization in models of cholestatic liver disease. In addition, ATP-independent, membrane potential-dependent transport routes for some mrp2/cmoat substrates (e.g., bilirubin glucuronide) are preserved in the mutant rats [16] . Taken together, these transport systems may explain residual canalicular conjugate transport under conditions with congenitally absent (mutant animals) or down-regulated mrp2 (cholestasis).
The human homologue of the canalicular conjugate export pump (MRP2) has also recently been cloned [12, 13] and the MRP2 protein is absent in the Dubin-Johnson syndrome [63] as a result of a mutation of the human MRP2 gene [64] . This syndrome is characterized by conjugated hyperbilirubinemia and a selective abnormality in the biliary excretion of a range of endogenous (bilirubin, coproporpyrin isomer series I) and exogenous anionic conjugates (BSP, ICG conjugates, the oral cholecystographic agent iopanoic acid), and is the human counterpart to the defect in GY/TR-and EHBR rats [14, 65] . However, patients with Dubin-Johnson syndrome are usually considered to be hyperbilirubinemic rather than cholestatic since there are no histological or biochemical signs of cholestasis. Whether bile flow is decreased in Dubin-Johnson syndrome patients, is not known.
Organic cations
The expression of P-glycoproteins (P-gp) at the canalicular membrane is dramatically increased in CBDL and a-naphthylisothiocyanate-induced cholestasis [51, 66, 67] but remains essentially unchanged in other forms of cholestasis induced by LPS and EE [51] , although one group has described a slight decrease in canalicular P-gp content (by 15 percent) in EE-induced cholestasis [67] . In rat liver, the increase in P-gp in CBDL and anaphthylisothiocyanate-induced cholestasis is mainly due to increased mdrl a and lb gene expression which is mainly accomplished through enhanced gene transcription [66] . In addition, the P-gp content of the canalicular membrane appears to be also regulated through biliary excretion of P-gp. Interestingly, P-gp release into bile is markedly impaired in CBDL, which could contribute to the increase in the hepatic P-gp content [67] . The resulting higher level of the biliary cation efflux pump mdrl P-gp may facilitate elimination of potentially toxic biliary constituents and thus prevent or limit hepatocellular damage in cholestasis. Indeed, the increased expression of mdrl P-gp results in increased biliary excretion of the mdrl substrate vinblastine [67] .
Knockout mice for the various mdrl isoforms have allowed an assessment of their role in hepatobiliary transport physiology and the pathogenesis of cholestasis. Mdrla(-/-) knockout mice have normal bile flow and biliary organic cation excretion is only modestly affected, since compensatory up-regulation of hepatic mdrlb expression occurs [68, 69] . Subsequently, mdrla/lb (-/-) double knockout mice have been developed to control for compensatory (over-) expression of mdrlb Pgp in the liver [70] . These animals are fully viable and, again, have normal bile flow, but biliary cation excretion is markedly impaired. The consequences of a mdrl defect may not become evident, unless exogenous toxins (that normally are eliminated via mdrl P-gp) are ingested with the food chain [69] . Mdrl substrates such as CSA inhibit ATP-dependent canalicular bile acid [31, 71] and organic anion transport [71] in the rat, and accumulation of such substrates may indirectly lead to cholestasis. Similarly, the phenotype of a human MDR1 defect would be expected to remain undetected unless challenged with a MDR1 substrate (e.g., under therapeutic conditions). Therefore, it could be possible that some forms of drug-induced hepatocellular cholestasis should occur in patients with such a defect. Phospholipids Biliary excretion of phospholipids is decreased in cholestasis induced by EE [66, 72] and CSA [72] , but is markedly increased in the first days following CBDL [66] and decreases after prolonged CBDL [73] . Both the decrease in canalicular P-gp content described in EE-induced cholestasis [67] and the marked increase in P-gp expression after the first days of CBDL [51, 66, 67] would provide a potential molecular mechanism for these functional alterations, although it was not demonstrated that these changes in P-gp expression involve the mdr2 isoform (phospholipid export pump).
The results in mdr2 (-/-) knockout mice have shown that a defect in biliary phospholipid secretion at the hepatocellular level can lead to cholangiopathy and severe liver disease [20, 75] . Therefore, the pathophysiology of a number of human neonatal and adult choletastatic syndromes deserves re-evaluation in the light of a possible MDR3 (human mdr2 homologue) defect. So far, MDR3 mRNA was found to be absent in one single patient with a subtype of progressive familial intrahepatic cholestasis (type 3) characterized by elevated serum gamma-glutamyl transpeptidase activity, as well as bile duct proliferation and inflammatory infiltrate in portal areas, thereby resembling the hepatic injury observed in mdr2 (-/-) mice, and the biliary phospolipid levels were substantially decreased in another patient with this disease [76] . However, no evidence for deficient or reduced intrahepatic MDR3 mRNA levels in liver biopsy samples from patients with primary biliary cirrhosis was found by reverse transcription/competitive polymerase chain reaction [77] , suggesting that decreased MDR3 gene expression does not play a role in the pathogenesis of primary biliary cirrhosis.
Cholesterol
Biliary cholesterol excretion is impaired in various experimental models of cholestasis such as EE-induced cholestasis [72] , CSA-induced cholestasis [73] and CBDL [74] . The detailed molecular mechanism for these findings remains currently unclear although impaired bile salt excretion observed in these models probably plays a major role [16, 78] .
Interestingly, a putative hepatic cholesterol carrier has been identified recently and awaits further characterization in experimental models of cholestasis [79] .
Glutathione
Biliary glutathione (GSH) excretion is markedly impaired in LPS-induced cholestasis [50] and CBDL [46, 80] and results in increased hepatocelluar GSH levels in these models of cholestasis [48, 50, 80] . In contrast to the decrease of biliary GSH excretion in livers from LPS-treated rats, GSH transport is normal in vitro in canalicular membrane vesicles isolated from these animals [81] . This finding of an apparent discrepancy between the intact liver and vesicle transport of GSH is reminiscent of what has been described in EHBR rats [82] with congenital absence of mrp2 (see above) where defective biliary GSH excretion is thought to be either a direct [24] or indirect effect [82, 83] of the mrp2 mutation. Impaired biliary excretion of GSH in mutant rats and these models of cholestasis could be best explained as a secondary defect due to cis-inhibition of canalicular GSH transport from retained substrates for the defective mrp2 and/or loss of trans-stimulation by these same substrates which are normally excreted into the bile canaliculus [82] . A recent report raised the possibility that MRP may transport GSH in cell lines transfected with MRP [84] , and it was, therefore, suggested that its canalicular isoform MRP2/mrp2 might also directly participate in canalicular GSH transport [17, 24] . Although this would provide a "unifying hypothesis" for both impaired biliary GSH excretion and impaired excretion of amphiphilic anionic conjugates under conditions with a congenital (e.g., mutant rats) or acquired (e.g., LPS, CBDL) mrp2 defect, a major role for MRP2/mrp2 in canalicular GSH transport appears unlikely, considering the fact that canalicular GSH transport is electrogenic (but not ATP-dependent) and bidirectional (but not unidirectional) as opposed to transport mediated by MRP2/mrp2 [83] . Bicarbonate Biliary HC03-excretion is markedly impaired in EE-induced cholestasis [85] and to a lesser degree in LPS-induced cholestasis [50] . However, in EE-treated animals, canalicular Cl7HC03-anion exchanger activity and its hormonal regulation are normal, and impaired biliary HCO3-excretion is apparently caused by regurgitation of biliary HC03-via leaky tight junctions from the bile canaliculus into the liver sinusoids [85] . In contrast, CBDL leads to increased biliary HCO3-excretion from proliferating bile ductules, particularly when stimulated with secretin [74] . No molecular data are so far available regarding the expression of Cl-/HCO3-anion exchanger (AE2) genes in these experimental models of cholestasis in rodents. However, recent studies in humans have revealed abnormal expression of AE2 in liver from patients with primary biliary cirrhosis [86] [87] [88] . AE2 immunoreactivity at canaliculi and bile ducts was decreased in such livers, and AE2 mRNA levels in liver tissue from these patients were also reduced. Since Cl-/HCO3--exchange activity is believed to be essential to secretion of both canalicular and ductular bile, decreased expression of AE2 in the liver may lead to impaired bile secretion. Diminished AE2 expression has also been reported in salivary glands from patients with primary biliary cirrhosis and Sicca syndrome [87] , which may indicate a more generalized epithelial "HC03-secretory failure" in PBC.
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